Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update [Yahoo! Finance]
MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
Company Research
Source: Yahoo! Finance
MoonLake Immunotherapeutics (NASDAQ: MLTX is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update MoonLake Immunotherapeutics (NASDAQ:MLTX) is placed eighth on our list of most promising stocks TheFly reported on February 26 that Goldman Sachs increased its price target on MLTX to $11 from $10 and maintained a Sell rating. The update followed the company's fourth-quarter and full-year results, with cash expected to fund operations into the second half of 2027 under its Hercules Capital facility. Although MLTX provided pipeline updates, the firm continues to question the likelihood of regulatory approval for sonelokimab. On February 22, MoonLake Immunotherapeutics (NASDAQ:MLTX) disclosed topline findings from the Phase 2 S-OLARIS study of SLK in individuals with radiographic and non-radiographic axial spondyloarthritis (axSpA). In the trial, 81% of
Show less
Read more
Impact Snapshot
Event Time:
MLTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLTX alerts
High impacting MoonLake Immunotherapeutics - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MLTX
News
- MoonLake Immunotherapeutics (MLTX) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have a "sector perform" rating on the stock.MarketBeat
- MoonLake Immunotherapeutics (MLTX) had its price target raised by HC Wainwright from $32.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- MoonLake Immunotherapeutics (MLTX) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at BTIG Research from $24.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at Needham & Company LLC from $20.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
MLTX
Earnings
- 2/25/26 - Miss
MLTX
Sec Filings
- 2/25/26 - Form 10-K
- 2/23/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- MLTX's page on the SEC website